Rationale and design of the MOTION study (monthly oral therapy with ibandronate for osteoporosis intervention).
Felicia Cosman(Helen Hayes Hospital), P. D. Delmas(Inserm), Vipul Devas, Clifford J. Rosen(MaineHealth), Sol Epstein, B El Azzouzi, Cyrus Cooper(University Hospital Southampton NHS Foundation Trust), José Zanchetta(Universidad del Salvador), B Bonvoisin, Michael R. McClung(Bone Health and Osteoporosis Foundation)
Journal of Bone and Mineral Research
January 1, 2005
Cited by 2
Related Papers
Effect of Parathyroid Hormone (1-34) on Fractures and Bone Mineral Density in Postmenopausal Women with Osteoporosis
|New England Journal of Medicine|2001|4.6k
Clinician’s Guide to Prevention and Treatment of Osteoporosis
|Osteoporosis International|2014|4.1k
The 2011 Report on Dietary Reference Intakes for Calcium and Vitamin D from the Institute of Medicine: What Clinicians Need to Know
|The Journal of Clinical Endocrinology & Metabolism|2010|4k
Denosumab for Prevention of Fractures in Postmenopausal Women with Osteoporosis
|New England Journal of Medicine|2009|3.5k
SCORE2 risk prediction algorithms: new models to estimate 10-year risk of cardiovascular disease in Europe
|European Heart Journal|2021|1.7k